A carregar...

Certolizumab pegol: a new biologic targeting rheumatoid arthritis

The past decade has been an exciting period for clinical research and patient care in rheumatoid arthritis. This is mostly due to targeted biologic agents that have changed the outcome of this disease. Certolizumab pegol (Cimzia®, UCB Inc., GA, USA), which targets TNF-α with a different mechanism of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Patel, Aarat M, Moreland, Larry W
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3971417/
https://ncbi.nlm.nih.gov/pubmed/20979550
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/eci.10.69
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!